Photo

Reuters Photojournalism

Our day's top images, in-depth photo essays and offbeat slices of life. See the best of Reuters photography.  See more | Photo caption 

Photo

Weird homes

Home is where the heart is, no matter what unusual form that home may take.  Slideshow 

Photo

The drone wars

The frontlines of America's covert drone program.  Slideshow 

Sponsored Links

Wall Street falls on weak data, Qualcomm drags

1 of 5. Traders work on the floor of the New York Stock Exchange, April 18, 2012.

Credit: Reuters/Brendan McDermid

NEW YORK | Thu Apr 19, 2012 6:57pm EDT

NEW YORK (Reuters) - Stocks fell for a second day on Thursday as labor market data showed more signs of weakness, while a warning from Qualcomm and poor results from Stanley Black & Decker also discouraged investors.

A late bounce cut the Dow's and the S&P 500's losses almost in half.

Apple shares, down 3.4 percent, also contributed to the day's losses, as did renewed concerns about Europe's finances. Apple closed at $587.44.

Spanish government bond yields increased after a disappointing debt auction and French bond yields rose on rumors, later denied, that the country's credit rating may be downgraded.

Qualcomm Inc led technology stocks lower, falling 6.6 percent to $62.57 a day after it warned of trouble meeting demand for some of its chips. Stanley Black & Decker fell 7.1 percent to $72.91, leading declines among industrials, the second worst-performing of the S&P 500's top 10 sectors.

The losses followed a strong start to earnings season, confirmed Thursday by better-than-expected reports from Bank of America Corp and Morgan Stanley.

Of the 105 S&P 500 components that have reported earnings to date, 81.9 percent have beat analysts' expectations, according to Thomson Reuters data.

"Despite the positive beat rate in earnings, some important economic data points have been losing momentum and that has to call into question whether or not this is just a soft patch or something more dramatic," said Quincy Krosby, market strategist at Prudential Financial in Newark, New Jersey.

"You overlay that with Europe again dominating the headlines ... it just has investors standing on the sidelines," she said.

Raising concerns about the economic outlook, new U.S. claims for unemployment benefits declined only slightly last week and were well above economists' expectations. Other reports showed factory activity in the Mid-Atlantic region slowed sharply in April and existing home sales dropped in March for a second straight month.

The Dow Jones industrial average fell 68.65 points, or 0.53 percent, to end at 12,964.10. The S&P 500 Index dropped 8.22 points, or 0.59 percent, to 1,376.92. The Nasdaq Composite lost 23.89 points, or 0.79 percent, to 3,007.56.

At their session lows, the three major indexes all fell more than 1 percent.

After the closing bell, Microsoft Corp reported a small drop in fiscal third-quarter profit that still beat Wall Street's forecast. Microsoft's stock rose 2.7 percent to $31.88 in extended-hours trading. In regular trading, Microsoft had slipped 0.4 percent to $31.01.

During the regular session, eBay Inc jumped 13.2 percent to $40.62 a day after the online auctioneer reported that its quarterly sales and profit grew more than expected. Late Wednesday, eBay also raised its 2012 forecasts.

Bank of America, the No. 2 U.S. bank, fell 1.7 percent to $8.77 after spending the morning higher. In contrast, Morgan Stanley rose 2.3 percent to $18.07. Both reported better-than-expected results. The S&P financial sector index fell 0.5 percent.

Biotechnology companies' gains helped shield the Nasdaq from a bigger loss, as the stock of Human Genome Sciences Inc soared 98 percent to $14.17 - nearly doubling its price in Thursday's session - and shares of Gilead Sciences Inc shot up 12.1 percent to $52.25.

Human Genome rejected an unsolicited $2.6 billion bid from long-time partner GlaxoSmithKline.

A combination of experimental hepatitis C drugs from Gilead and Bristol-Myers Squibb Co showed impressive results in new clinical trial data released on Thursday.

The Nasdaq biotech index climbed 1.5 percent.

About 7.43 billion shares changed hands on the New York Stock Exchange, the Nasdaq and the NYSE Amex, compared with the average 6.78 billion so far this year.

Declining issues beat advancers on the NYSE by a ratio of about 7 to 5 while on the Nasdaq, five issues fell for every three that rose.

(Reporting by Rodrigo Campos; Editing by Jan Paschal)

We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see http://blogs.reuters.com/fulldisclosure/2010/09/27/toward-a-more-thoughtful-conversation-on-stories/
Comments (5)
justsayin2011 wrote:
Clearly, they aren’t listening. barack and company clearly stated it would be all better by now. What’s wrong with all these people? Just believe, believe, believe. Pixie dust and idiot dust only work if you truly believe.

Apr 19, 2012 3:28pm EDT  --  Report as abuse
Venerability wrote:
No, unrelenting negativity from Bubblevision and the rest of the irresponsible world financial media made markets fall on a day most of the news was GOOD.

At the exact time it is important for commentators to act like responsible Adults, they are talking up the Short side and “taking it to the limit,” just when they should take time to think – as they did not in 2008 – that “the limit” may be a precipice.

It’s time for the Kiddies to get off the air and off the world stage, while Adults with the world economy’s best interests at heart take their place.

Apr 19, 2012 3:36pm EDT  --  Report as abuse
Grant_X wrote:
Justsayin, when has trickle down economics ever benifitted anyone other than the ultra rich? What jobs has this economic philosophy created? Can you name one?

Apr 19, 2012 3:51pm EDT  --  Report as abuse
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.